Q3 2025 Alligator Bioscience AB Earnings Call Transcript
Key Points
- Alligator Bioscience AB (STU:7AL0) announced positive 30-month follow-up data from the Phase II study of mitazalimab in first-line metastatic pancreatic cancer, confirming long-term survival benefits.
- The company successfully executed a SEK120 million rights issue with a secured level of 65%, providing financial runway into 2026.
- Alligator Bioscience AB has initiated several externally funded Phase II studies to expand the development options for mitazalimab.
- The company signed an agreement on its antibody technology, RUBY, demonstrating the platform's potential for monetization.
- The first US patient was dosed in a global Phase III study with HLX22 in gastric cancers, potentially generating future milestones and royalty revenues.
- The company continues to face high operational costs, although efforts are being made to reduce them.
- Alligator Bioscience AB is reliant on the successful completion of the rights issue to maintain financial stability.
- The company has not yet secured a partnership for mitazalimab, which is crucial for advancing its development.
- There are ongoing costs associated with the Phase II study closure and manufacturing, impacting financials.
- The development of 4066, a next-generation CD40 molecule, is on hold pending the partnership of mitazalimab.
¶¶ -
So hello, everybody, and welcome to the Alligator Bioscience Interim Report Call for the third quarter of 2025. My name is Greta Höög. I am the IR and Communications Manager at Alligator, and I will be introducing today's call.
With me are our CEO, Søren Bregenholt; and our CFO, Johan Gileus, and they will walk you through the latest developments in the company from this quarter and the upcoming news flow, after which, they will be happy to take any questions that you may have. These can be submitted to the Q&A function of this webinar or emailed to [email protected].
Now as you all know, Alligator is a publicly listed company, and I'd like to note that today's presentation may include such things as forward-looking statements. Please refer to the disclaimer on this slide, which applies to the full presentation.
And with that, over to you, Søren.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
